Spinal Muscular Atrophy (SMA) Mouse Model Development Service

Creative Biolabs provides custom spinal muscular atrophy (SMA) mouse model development and preclinical study support for SMN biology, disease-mechanism studies, therapeutic-window definition, target validation, pharmacokinetic/pharmacodynamic analysis, biomarker development, and efficacy testing.

We help clients select or engineer the appropriate severe, intermediate, mild, inducible, conditional, humanized, or reporter model; establish and genetically qualify breeding colonies, map an age-resolved phenotype window, and execute studies for antisense oligonucleotides, SMN2 splicing modifiers, gene-replacement vectors, genome or RNA editing, pathway modulators, and combination therapies.

Programs can be linked with the broader spinal muscular atrophy model development service, the SMA drug discovery service, and the A-Z™ SMA drug discovery platform.

Match Genotype and Severity to the Required Evidence

Human SMN2 copy number, transgene integrity and expression, the residual function of murine Smn alleles, modifier loci, strain background, breeding direction, maternal environment, litter size, sex, husbandry, and experimental handling can shift survival and neuromuscular phenotypes.

When the optimal line already exists, the work can focus on importation, rederivation if required, colony rebuilding, baseline confirmation, and study execution. When the necessary disease window, tissue specificity, reporter, or human sequence is not available, a custom allele or transgene can be designed. A feasibility gate compares engineering time, breeding complexity, expected phenotype, available controls, and whether a tunable or conditional strategy would answer the question with less biological ambiguity.

For portfolio planning, mouse work can be paired with SMA C. elegans model development or SMA zebrafish model development to prioritize mechanisms and treatments before committing to a longer mammalian study.

Generate, Breed, and Genetically Qualify the Colony

Genetic Design and Founder Strategy

For custom models, the design package specifies the target allele, human sequence or variant, donor architecture, conditional or tissue-specific elements, reporter, promoter or regulatory context, strain background, genotyping assays, predicted breeding path, and required control animals. CRISPR/Cas editing, knock-in, knockout, transgenic, humanized, reporter, or conditional strategies can be evaluated. Candidate founders are assessed for on-target sequence, zygosity, allele transmission, potential mosaicism, unintended linked changes, and reproductive performance. Independent founders or lines can be retained when insertion site, expression level, or founder-specific effects could confound interpretation.

Breeding Scheme, Colony Scale, and Cohort Forecasting

The breeding plan works backward from the number, genotype, sex, and age of animals required for qualification and efficacy. It incorporates Mendelian yield, nonproductive genotypes, preweaning loss, breeder replacement, litter-size distribution, timed-mating capacity, synchronization needs, and contingency inventory. For neonatal severe models, the plan also defines rapid genotyping or marker-based identification, within-litter allocation, fostering rules, dosing order, and sample-collection logistics. Colony forecasts are updated using observed breeding and survival data rather than fixed theoretical yield.

Genetic, Molecular, and Phenotypic Qualification

Genetic qualification can include junction PCR, amplicon or Sanger sequencing, digital or quantitative copy-number analysis, zygosity, transgene integrity, off-target review where appropriate, and confirmation of the relevant background. Molecular qualification can measure SMN1 or SMN2 transcripts, SMN2 exon 7 inclusion, full-length SMN protein, tissue distribution, nuclear gems, and downstream RNA-processing or pathway markers. Phenotypic qualification then establishes survival, growth, motor behavior, electrophysiology, neuromuscular-junction integrity, motor-neuron abundance, muscle pathology, systemic features, and the age at which signals become stable enough for intervention testing.

Variance Control and Reproducibility

Litter, sex, genotype, body weight, baseline function, breeder pair, technician, cage, test time, and assay batch can all influence apparent treatment response. The protocol therefore defines group allocation, litter balancing, randomization, blinding, handling and acclimation, equipment calibration, assay order, prespecified exclusions, repeat rules, sample tracking, and statistical units. Historical control data may inform planning, but concurrent controls remain central when colony conditions or model tempo can drift.

Connect Motor Function with Neuromuscular and Molecular Biology

No single endpoint is sufficient across all disease severities. Survival can be decisive in a severe model but may be uninformative in a mild line; grip strength may be feasible in older mice but impossible in a rapidly progressive neonatal model. We therefore build an age-appropriate hierarchy of primary, supportive, and exploratory endpoints.

• Survival, growth, and clinical progression
• Motor function and activity
• Electrophysiology and motor-unit function
• Neuromuscular-junction and motor-neuron pathology
• Muscle and systemic pathology
• SMN biology and target engagement
• Pharmacokinetics, safety, and immunogenicity

Specialized motor and efficacy endpoints can be incorporated through motor function disability disease model development services, in vivo services, and in vitro, in vivo and ex vivo electrophysiology assays.

Related Research

A Splice-Promoting Compound Creates a Tunable SMA Severity Window

Rietz and colleagues used controlled exposure to the SMN2 splice-promoting compound NVS-SM2 to modify the course of a severe SMA mouse model. Treatment schedules produced distinct survival, body-weight, and tail-length trajectories, including longer-lived phenotypes after limited early treatment.

Fig. 1 Limited NVS-SM2 treatment produces graded survival, body-weight, and tail-length phenotypes in a tunable SMA mouse model.^1,3

Muscle Growth Improves Without Correcting the Motor-Unit Deficit

Liu and colleagues evaluated activin receptor type IIB pathway inhibition in the mild C/C SMA mouse model. Histological analysis showed increased muscle fiber size and related muscle improvements, while the broader study found that motor-unit number was not restored. This separation is directly relevant to endpoint planning. A muscle-directed intervention may improve mass, fiber morphology, or force without correcting denervation or motor-neuron loss; conversely, a neural intervention may preserve motor units before gross muscle measures change.

Fig. 2 Muscle histology and fiber-size analysis in wild-type and C/C SMA mice after activin receptor type IIB pathway inhibition.^2,3

Frequently Asked Questions

1. Which SMA mouse models can Creative Biolabs develop or provide?

   Creative Biolabs can support severe SMNΔ7 and SMN2 transgenic models, intermediate Smn2B/− or related allelic models, mild C/C or higher-copy SMN2 models, inducible and conditional strategies, and custom humanized, variant, reporter, or tissue-specific mice. Model choice is based on the therapeutic modality, intended disease stage, required study duration, endpoint sensitivity, and translational claim.

2. How do I choose between a severe, intermediate, and mild SMA model?

   A severe model is useful for rapid proof-of-concept and survival rescue but has a narrow neonatal window. An intermediate model permits repeated dosing, serial function testing, and broader neuromuscular physiology. A mild model is better for chronic pathology, subtle motor-unit deficits, and longer safety or combination studies. We compare the expected baseline effect, intervention timing, assay dynamic range, welfare burden, and sample-size requirement before recommending a model.

3. Can SMN2 copy number, genetic background, or tissue specificity be customized?

   Yes. Depending on feasibility and study purpose, the program can address SMN2 copy configuration, allele combinations, congenic or mixed background, conditional alleles, tissue-specific drivers, reporters, and human sequence or variant constructs. Copy number, zygosity, expression, background, and segregation behavior are incorporated into the qualification plan because each can materially change disease tempo.

4. How is an SMA mouse colony qualified before efficacy testing?

   Qualification may include allele and transgene genotyping, copy-number or zygosity assessment, pedigree and breeding review, SMN transcript and protein measurement, SMN2 exon 7 inclusion, survival and growth curves, motor-function baselines, neuromuscular-junction and motor-neuron pathology, muscle histology, and electrophysiology. Acceptance criteria are defined before the efficacy cohort is launched.

5. Which functional and neuromuscular endpoints are available?

   Available endpoints can include righting reflex, hindlimb suspension, grip strength, rotarod, open-field activity, gait, respiratory or whole-body physiology, compound muscle action potential, motor-unit number estimation, electromyography, neuromuscular-junction occupancy, motor-neuron counts, muscle fiber size and type, SMN expression, splice correction, biodistribution, and project-specific biomarkers.

6. Can the models be used for ASO, small-molecule, AAV, or gene-editing studies?

   Yes. Study designs can be adapted for antisense oligonucleotides, SMN2 splicing modifiers, AAV or other gene-replacement approaches, genome or RNA editing, protein or pathway modulators, and combination regimens. Route, dose volume, age at treatment, redosing feasibility, target-tissue exposure, immunogenicity risk, and target-engagement sampling are planned around the modality.

7. How are litter effects, randomization, blinding, and animal welfare handled?

   The protocol can balance genotype, sex, litter, body weight, and baseline performance across groups; distribute treatments within litters where feasible; randomize dosing and assessment order; blind functional, histological, and image analysis; and prespecify exclusion and humane-endpoint rules. Neonatal identification, sample collection, fostering, and handling are standardized to reduce avoidable variance and welfare burden.

8. Can an SMA mouse study be connected to C. elegans or zebrafish work?

   Yes. Rapid invertebrate or zebrafish work can prioritize targets, genetic modifiers, dose ranges, and mechanism hypotheses before mouse confirmation. The mouse study can then focus on mammalian pharmacokinetics, tissue distribution, motor-unit physiology, respiratory or systemic biology, and translational efficacy. Cross-model plans use aligned endpoints where possible while respecting the biological limits of each species.

9. What information is needed to start an SMA mouse model development project?

   Helpful inputs include the disease mechanism and desired severity, preferred genotype or available parental strains, therapeutic modality, route and dosing age, intended study duration, primary and secondary endpoints, target tissues, molecular and biomarker assays, biospecimen needs, comparator treatment, expected effect size, timeline, and model-acceptance or efficacy go/no-go criteria.

References

1. Rietz, Anne, et al. "Short-Duration Splice Promoting Compound Enables a Tunable Mouse Model of Spinal Muscular Atrophy." Life Science Alliance, vol. 4, no. 1, 2021, article e202000889. https://doi.org/10.26508/lsa.202000889
2. Liu, Min, et al. "Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy." PLOS ONE, vol. 11, no. 11, 2016, article e0166803. https://doi.org/10.1371/journal.pone.0166803
3. Distributed under Open Access license CC BY 4.0, without modification